Additionally, tumor molecular markers, such as the microsatellite status, the CpG island methylator phenotype (CIMP) status, driver gene mutations, such as KRAS and BRAF, and tumor immune microenvironment, have been linked to different recurrence risks of stage III colon cancer [34, 35]. This evidence concerns the gene KRAS and neoplasm.